AlphaQuest’s Arcturus Therapeutics ARCT Stock Holding History

AlphaQuest’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,727	Closed	-$145K	–	151
2025 Q4	$145K	Buy	23,727 +11,364	+92%	+$123K	0.01%	1587
2025 Q3	$228K	Sell	12,363 -8,099	-40%	-$130K	0.01%	1334
2025 Q2	$266K	Sell	20,462 -14,820	-42%	-$175K	0.03%	960
2025 Q1	$374K	Buy	35,282 +28,140	+394%	+$447K	0.04%	669
2024 Q4	$121K	Sell	7,142 -12,668	-64%	-$238K	0.02%	1042
2024 Q3	$460K	Buy	19,810 +16,122	+437%	+$345K	0.04%	691
2024 Q2	$89.8K	Buy	3,688 +3,579	+3,283%	+$109K	0.01%	953
2024 Q1	$3.68K	Sell	109 -2,004	-95%	-$71K	﹤0.01%	1105
2023 Q4	$66.6K	Buy	+2,113	New	+$50.2K	0.01%	840

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaQuest's ARCT Position: Q1 2026 in Review

AlphaQuest sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 23,727 shares — an estimated $145K sold.

AlphaQuest first reported a position in ARCT in Q4 2023 and held it in 9 quarters. The position peaked at $460K in Q3 2024. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

AlphaQuest reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 23,727 Arcturus Therapeutics shares in Q1 2026, an estimated $145K.
AlphaQuest first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 9 quarters.
AlphaQuest's Arcturus Therapeutics position peaked at $460K in Q3 2024.
124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.